Bixiye
QP44-24 MHCP Pharmacy Benefit Exclusion for Anktiva® and Docivyx™
Taariikhda uu dhaqangalayo Barnaamijka: May 22, 2024
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1451 - 1460 ee natiijooyinka 3167
Bixiye
QP38-24 Training Webinars for New Prior Authorization Submission Process
Taariikhda uu dhaqangalayo Barnaamijka: May 22, 2024
Bixiye
QP37-24 Update for New-to-Market Medical Drugs: atidarsagene autotemcel, crovalimab, and fidanacogene eleparvovec
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP39-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective July 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP40-24 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective June 1, 2024
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP43-24 MHCP Pharmacy Benefit Exclusion for Alyglo™ and Lenmeldy™
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP42-24 Commercial Pharmacy Benefit Exclusion for Lenmeldy™
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
QP41-24 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: May 08, 2024
Bixiye
P32-24 eviCore Healthcare Specialty Utilization Management (UM) Program: Medical Oncology Drug Prior Authorization Updates
Taariikhda uu dhaqangalayo Barnaamijka: May 01, 2024
Bixiye
P31-24 2024 Renewal Changes Summary for Blue Plus Referral Health Professional Providers
Taariikhda uu dhaqangalayo Barnaamijka: May 01, 2024